CERo confirms research partnership and $40 million funding round
Category: #health  | By Mateen Dalal  | Date: 2020-03-20 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

CERo confirms research partnership and $40 million funding round

CERo Therapeutics, Inc., the privately-owned biopharma firm, recently announced that it will be collaborating for research with Lyell Immunopharma, Inc. for the development of next-gen cell-based immunotherapy solutions to treat solid tumors. CERo also announced that it completed its Series A private financing, securing $40 million.

Apparently, the terms of the agreement demands Lyell and CERo to collaborate for pursuing the proof-of-concept studies for the new class of cell-based therapeutics, mainly directed against solid tumors. The CER-T technology of CERo directs the immune cells to occupy complementary and novel tumor cell clearance pathways that are designed to facilitate sustained and deeper responses against all the broad tumor classes.

The Chief Executive Officer and Co-founder of CERo, Daniel Corey, MD, commented that the company’s technology tends to combine several forms of tumor cell clearance and further introducing all of them into single cells to be able to largely expand the therapeutic potential.

Corey further added that Lyell stands as an ideal partner for CERo with its advanced T-cell capabilities. The company believes that both the platforms exhibit powerful therapeutic synergies.

Lyell Immunopharma’s Chief Executive Officer and Founder, Rick Klausner, MD, stated that CERo has been developing an innovative therapeutic class by leveraging the understandings from synthetic biology and innate immunology. 

For the record, Lyell Immunopharma Inc. is essentially a cell therapy firm that is dedicated to developing and understanding technologies helping in overcoming the basic barriers to other curative therapies. The company has placed its focus on advancing science of functionality, target specificity and T-cell differentiation to be able to build curative treatments for different human diseases.

The Series A private financing had included Milky Way Investments Group Limited, Sequoia Capital China, ARCH Venture Partners, Lyell Immunopharma, Inc., as well as the existing shareholders of CERo and has raised $40 million. The proceeds secured from the financing are now being used for the expansion of startup operations and advancing the propriety CER-T technology platform of the company into the clinic.  
 

Source Credit- https://www.cero.bio/news/press-releases/031820/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

AWS and ATOS expand collaboration to achieve digital transformation faster

AWS and ATOS expand collaboration to achieve digital transformation faster

By Mateen Dalal

Amazon's subsidiary, Amazon Web Services, Inc. (AWS), has recently entered into a global Strategic Transformation Agreement with Atos, a leader in digital transformation, high-performance computing, and information technology infrastructure. This...

LadBible to lay off 10% of its workforce amid tough business conditions

LadBible to lay off 10% of its workforce amid tough business conditions

By Mateen Dalal

LadBible, one of the U.K.'s largest success stories in online media, is laying off 10% of its workforce as a result of a decline in its share price and a warning about difficult trading conditions. The Manchester-based corporation reportedly b...

Oral-B & iADH partner to make oral care positive & accessible for all

Oral-B & iADH partner to make oral care positive & accessible for all

By Mateen Dalal

Oral-B, a well-known American oral hygiene products brand, has reportedly inked a partnership deal with iADH (International Association of Disability and Oral Health), in order to make oral care more positive, accessible, and inclusive for disabled p...